Semaglutide powers Novo Nordisk's blockbuster drugs Ozempic and Wegovy, which have ignited worldwide demand for diabetes and weight-loss therapy.
Following this assurance, the Court permitted Sun Pharma to manufacture and export semaglutide solely to jurisdictions where no conflicting Novo Nordisk patent exists. The undertaking was recorded in the ongoing suit Novo Nordisk vs. Sun Pharma, where the Danish innovator has accused the Indian drugmaker of infringing its semaglutide patent.
Earlier, the Medical Dialogues Team had reported that Novo Nordisk approached the Delhi High Court to restrain Sun Pharmaceutical from dealing, directly or indirectly, in semaglutide, the core molecule powering its global blockbuster Ozempic. The company has sought a restraint on Sun Pharma from handling either the API or any product derived from it.
Prior to this, the Delhi High Court had refused to grant Danish innovator Novo Nordisk an interim injunction to restrain Dr. Reddy's Laboratories from manufacturing Semaglutide in India. The court had permitted Dr. Reddy’s to continue manufacturing Semaglutide in India but barred domestic sale until the patent expires.
In continuation to the legal battle over Semaglutide patent, Novo Nordisk filed new lawsuit against Sun Pharma, wherein the case was brought before Justice Tejas Karia, who observed the similarities with the previous Dr. Reddy's Laboratories case and moved the case to Justice Manmeet Pritam Singh Arora's bench.
During the hearing, when Sun Pharma attempted to rely on a December 2 ruling in a related case involving the same patent, Justice Manmeet Pritam Singh Arora firmly reminded counsel that the benefit of that judgment came with strict compliance conditions.
The judge reiterated, “Export to countries in which they don’t have patents. That is the affidavit in that matter,” and instructed Sun Pharma to submit an affidavit within two weeks to formally affirm this undertaking.
Sun Pharma also acknowledged that it is already manufacturing the drug. The Court further required the company to submit quarterly account statements, detailing export and other relevant figures, up to March 2026, mirroring directions previously issued in the earlier suit, reports Bar and Bench.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.